SMARCA4-Deficient Undifferentiated Tumor Presenting as a Tonsillar Mass With Widespread Metastases: A Rare Head and Neck Manifestation and Complete Response to Chemoimmunotherapy

By afschroeder • September 23, 2025

Huynh J, Segal J, Eisenbud L, Gutierrez R, Slomowitz SJ. SMARCA4-Deficient Undifferentiated Tumor Presenting as a Tonsillar Mass With Widespread Metastases: A Rare Head and Neck Manifestation and Complete Response to Chemoimmunotherapy. Cureus. 2025 Aug 21;17(8):e90665. doi: 10.7759/cureus.90665. PMID: 40978837; PMCID: PMC12449849.

Tags: cancer immunotherapy, Hematology/Oncology, pembrolizumab, Publications, smarca4 deficient, smarca4-deficient undifferentiated tumor, thoracic smarca4-deficient undifferentiated tumor

Related Posts

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial

Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG,[...]

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results

Deng J, Pal A, Testa S, Xu JW, Tran LM, Graham DS, Hargil A, Subramanian A, Campbell KM, Limsuwannarot S, Chumpitaz Lavalle Á, Chin SC,[...]

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD

Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z, Hendriks LEL, Morabito A, Bonanno L, Brustugun OT, Halvorsen TO, Kim YJ,[...]